Open an account

Syros Pharmaceuticals

SYRS · OTC

$0.0004+$0.00 (+0.00%)TodayMarket closed ·
Prev close $0.0004

SYRS analyst rating

This isn't available right now. Refresh to try again.

The case for and against

Updated Apr 24, 2025

Bull case

Syros Pharmaceuticals's strategic approach to streamlining the trial processes may lead to reduced operational expenses and expedite therapy delivery for hematologic malignancies, potentially enhancing market competitiveness. The promising early clinical data indicating a higher complete response (CR) rate for tamibarotene combined with azacitidine compared to control treatments underscores the therapeutic potential that could positively influence investor sentiment. Additionally, Syros maintains a solid financial position, with sufficient cash reserves to cover anticipated operational expenses through at least the third quarter of 2025, supporting continued investment in its clinical trials and development programs.

Bear case

Syros Pharmaceuticals Inc.'s negative outlook stems from several fundamental challenges, including the termination of its collaboration agreement with Pfizer, which led to the removal of tamibarotene from its valuation. Additionally, the recent failure of the Phase 3 SELECT-MDS-1 trial to meet its primary endpoint significantly undermines the potential for tamibarotene in treating higher-risk myelodysplastic syndrome, further complicating the company's revenue prospects. The financial health of Syros is also called into question, as evidenced by a net loss of $6.4 million in the latest quarter, raising concerns about its ability to sustain operations amid escalating risks and competition in a constrained market.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.